Simon Barry J. 4

What Happened
Simon Barry, a director of ImmunityBio, sold 75,000 shares of IBRX stock on February 24, 2026. The aggregate reported value of the sale is $900,788; the weighted average price reported is $12.01 per share (sales occurred in a $12.00–$12.025 price range). This was a sale (not a purchase), and sales by insiders are often routine rather than a direct signal of company prospects.

Key Details

• Transaction date: February 24, 2026 (reported on Form 4 filed February 26, 2026).
• Transaction type/code: Sale (S) — open-market or private sale.
• Price details: Weighted average price $12.01; price range $12.00 to $12.025.
• Total reported proceeds: $900,788.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: Sale was effected under a Rule 10b5-1 trading plan adopted by Mr. Barry on September 4, 2024.
  • F2: Weighted average reflects an aggregate sale in the $12.00–$12.025 range; Mr. Barry can provide per-price breakdowns to the SEC, the issuer, or shareholders upon request.
• Filing timeliness: Form 4 was filed on Feb 26, 2026, within the typical two-business-day reporting window (timely).

Context
Because the sale was executed under a pre-established 10b5-1 trading plan, it was likely pre-scheduled and may not reflect Mr. Barry’s current view of the company. For retail investors, purchases generally carry more inference about insider confidence; routine sales under 10b5-1 plans are common and not uncommon to see.